Accéder au contenu
Merck
Toutes les photos(1)

Documents

SML3205

Sigma-Aldrich

Sitagliptin

≥98% (HPLC)

Synonyme(s) :

(2R)-4-Oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine, (3R)-3-Amino-1-[5,6-dihydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a ]pyrazin-7(8H )-yl]-4-(2,4,5-trifluorophenyl)-1-butanone,, MK 0431 free base, MK 431 free base, MK-0431 free base, MK-431 free base, MK0431 free base, MK431 free base

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C16H15F6N5O
Numéro CAS:
486460-32-6
Poids moléculaire :
407.31
Numéro MDL:
MFCD09838015
Code UNSPSC :
51111800
Nomenclature NACRES :
NA.77

Niveau de qualité

100

Pureté

≥98% (HPLC)

Forme

powder

Activité optique

[α]/D -17 to -23°, c = 0.5 in chloroform-d

Couleur

white to beige

Solubilité

DMSO: 2 mg/mL, clear

Température de stockage

−20°C

InChI

1S/C16H15F6N5O/c17-10-6-12(19)11(18)4-8(10)3-9(23)5-14(28)26-1-2-27-13(7-26)24-25-15(27)16(20,21)22/h4,6,9H,1-3,5,7,23H2/t9-/m1/s1

Clé InChI

MFFMDFFZMYYVKS-SECBINFHSA-N

Actions biochimiques/physiologiques

Sitagliptin is an orally active, potent and selective dipeptidyl peptidase IV (DPP4; DPP-IV) inhibitor (IC50 = 18 nM) with excellent selectivity over other proline-selective peptidases (IC50 = 48 μM/DPP8, >100 μM/DPP9 & QPP). Sitagliptin improves glucose tolerance in lean mice (23% and 55% reduction of blood glucose post 5 g dextrose/kg with 0.1 or 3 mg Sitagliptin/kg p.o. 60 min prior to dextrose challenge) and in DIO mice (68% and 90% reduction of blood glucose post 2 g dextrose/kg with 0.3 or 3 mg Sitagliptin/kg p.o.) as a result of DPP-IV inhibition and upregulated GLP-1 level in blood in vivo.

Pictogrammes

Health hazardExclamation mark
GHS08,GHS07

Mention d'avertissement

Warning

Mentions de danger

H319,H373

Classification des risques

Eye Irrit. 2 - STOT RE 2

Organes cibles

Liver

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Heba A Habib et al.
Life sciences, 278, 119624-119624 (2021-05-19)
Diabetic nephropathy, a major threat to diabetic patients, is considered as the main reason for end-stage renal disease. Fortunately, incretin-based therapy has been aroused as considerable source to attenuate diabetic renal damage. This study aimed to investigate whether superior protective
Yossra Ahmed et al.
Journal of diabetes and metabolic disorders, 20(1), 551-560 (2021-07-06)
Emerging evidence suggests that mesenchymal stem cells (MSCs) have many anti-inflammatory and regenerative properties, which makes it a suitable candidate for the treatment of many diseases including metabolic syndrome (MetS). However, a major difficulty with stem cell therapy is to
Mohamed Abouelkheir
Current molecular pharmacology (2021-06-03)
We previously tested two angiotensin-converting enzyme (ACE) inhibitors and two dipeptidyl peptidase-4 (DPP-4) inhibitors for dual enzyme inhibitory effect. Only two DPP-4 inhibitors, linagliptin and sitagliptin, were able to inhibit ACE. In the present study, we investigated if other inhibitors
Rui Li et al.
Frontiers in oncology, 11, 679816-679816 (2021-06-15)
Cancer has been as one of common comorbidities of diabetes. Long-term antidiabetic treatment may potentially exert uncertain impacts on diabetic patients with cancer including breast cancer (BC). Dipeptidyl peptidase-4 inhibitors (DPP-4i) are currently recommended by the AACE as first-line hypoglycemic
Soraya Mehrdoost et al.
Iranian journal of basic medical sciences, 24(4), 451-459 (2021-06-08)
Fatty liver disease (FLD) is a disorder related to accumulation of excess fat within the hepatocytes. In this study, the effects of Berberine, a natural compound, and Sitagliptin as a DPP-4 inhibitor, were observed in a rat model of FLD.
Afficher tous les articles scientifiques apparentés

Contenu apparenté

Interrogation des voies protéiques

L'interrogation des voies protéiques est un élément fondamental de la recherche de nouveaux médicaments et de leur développement. Apprenez-en davantage sur l'analyse des voies protéiques, notamment le criblage de banques de composés chimiques, l'étude de l'activité des protéines et des enzymes, et la modulation des voies protéiques à l'aide de petites molécules.

Protein Pathway Interrogation

Explore protein pathway analysis including chemical library screening and modulating pathways with small molecules.

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique